Lupin has received approval from the US health regulator to market anti-inflammatory Clobetasol Propionate lotion in the American market.
The Mumbai-based firm said in a statement today that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The company’s product is a generic version of Galderma Laboratories’ Clobex lotion, which is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
As per IMS MAT June data, Clobex had sales of $14.3 million in the US market.
Lupin shares ended the session down by 2.03 per cent at Rs 993 on the BSE.